Evaluation of cyclic nucleotide phosphodiesterase III inhibitors in animal models of epilepsy

Biomedical Research

Volumn 19, Issue 1, 2008, Pages 13-17

  Nandhakumar, J ^b   Tyagi, Manoj G ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

^b NANDHA COLLEGE OF PHARMACY   (India)

Author keywords

Amrinone; Mice; Milrinone; PDE 3 inhibitors; Seizures

Indexed keywords

AMRINONE; ISONIAZID; MILRINONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; ELECTRIC SHOCK; EPILEPSY; EVALUATION; FEMALE; MALE; MOUSE; NONHUMAN;

ANIMALIA; MUS;

EID: 43049127216     PISSN: 0970938X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Delgado-Escueta AV, Treiman DM, Walsh GO. The treatable epilepsies. N. Engl J Med 1983; 308: 1508-1514.
2. Jeon YH, Heo YS, Kim CM, Hyun YL, Lee TG, Ro S, Cho JM. Phosphodiesterase : overview of protein structures, potential therapeutic applications and recent progress in drug development. Cell Mol Life Sci 2005; 62: 1198-1220.
3. Smith CJ, Krall J, Manganiello VC, Movsesian MA. Cytosolic and şarcoplasmic reticulum-associated low Km, cGMP-inhibited cAMP phosphodiesterase in mammalian myocardium. Biochem Biophys Res Commun 2005; 190: 521-561.
4. Shakur Y, Holst LS, Landstorm TR, Mowsesian M, Degermen E, Manganiello V. Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family. Prog. Nucleic. Acid Res Mol Biol 2001; 66: 241-277.
5. Ray A, Gulati K, Anand S, Vijayan VK. Pharmacological studies on mechanisms of amninophylline-induced seizures in rats. Ind J Exp Biol 2005; 43: 849-853.
6. Cho CH, Cho DH, Seo MR, Juhnn YS. Differential changes in the expression of cyclic nucleotide phosphodiesterase isoforms in rat brains by chronic treatment with electroconvulsive shock. Exp Mol Med 2000; 32: 110-114
7. Liu H, Maurice DH. Expression of cyclic GMP-inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: differential subcellular localization and regulated expression by cyclic AMP. Br .J Pharmacol 1998; 125: 5101-1510
8. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995; 75: 725-748
9. Suda S, Nibuya M, Ishiguro T, Suda H. Transcriptional and translational regulation of phosphodiesterase type IV isozymes in rat brain by electroconvulsive seizure and antidepressant drug treatment. J Neurochem 1998; 71: 1554-1563
10. Takahashi M, Terwilliger R, Lane C, Mezes PS, Conti M, Duman RS. Chronic antidepressant administration increases the expression of cAMP- specific phospodiesterase 4A and 4B isoforms. J Neurosci 1999; 19: 610-618
11. Costa E, Guidotti A, Mao CL. Evidence for involvement of GABA in the action of benzodiazepines; studies on rat cerebellum. In: Costa E, Greengard P (eds) Mechanisms of action of benzodiazepines. Advances in Biochemical Psychopharmacology, Vol 14. Raven Press, New York 1975. pp. 113-151
12. Tyagi MG, Jose VM. Anticonvulsant effect of cytoskeletal depolymerizers in combination with potassium channel opener and adenylate cyclase activator; a causative link with nerve growth factor? Ind J Exp Biol 2001; 39: 425-430,
13. Barnes PJ. Theophylline: in Asthma: Basic mechanism and clinical management, edited by Barnes PJ, Rodger IW and Thompson N C, (Academic Press, San Diego, USA) 1998, 689
14. Barnes PJ, Pauwels RA. Theophylline in the management of asthma: Time for reappraisal. Eur Respir J 1995; 7: 579
15. Peter Honerjager. Pharmacology of bipyridine phosphodiesterase 3 inhibitors. American Heart Journal 1991; 121: 1939-1944
16. Masaaki Ito, Toshio Tanaka, Masahiro Saitoh, Hiroshi Masuoka, Takeshi N, Hiroyoshi H. Biochemical pharmacology 1988; 37: 2041-2044
17. Cruickshank JM. Phosphodiesterase III inhibitors: long term risks and short-term benefits. Cardiovasc Drugs Ther. 1993; 7: 655-660
18. Wetzel B, Hauel N. New cardiotonic agents- a promising approach for treatment of heart failure. TIPS 1998; 9: 166-170
19. Vullimoz Y, Verosky M, Alpert M, Triner L. Effect of enflurane on cerebellar cGMP and on motor activity in the mouse. Br.J.Anesthesia 1983; 55: 79-84
20. Riazi K, Roshanpour M, Rafei-Tabatabaei N, Homayoun H, Ebrahimi F, Dehpour AR. The proconvulsant effect of sildenafil in mice: role of nitric oxide-cGMP pathway. Br.J. Pharmacol 2006; 147: 935-943
21. Walaas S.I., Greengard P. Protein phosphorylation and neuronal function. Pharmacol. Rev 1991; 3: 299-349
22. 2+/Calmodulin- dependent kinase II alpha-subunit mutation. Proc Natl Acad Sci USA. 1995; 15: 6852-6855
23. Francis SH, Turko IV, Corbin JD. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog. Nucleic Acid Res. Mol Biol 2001; 65: 1-52
24. Lebel CP and Bondy S C. Oxygen radicals: Common mediators of neurotoxicity. Neurotoxicol Teratol 1991; 13:, 314